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Diethanolamine (DEA) is a common ingredient of personal care
products. Dermal administration of DEA diminishes hepatic
stores of the essential nutrient choline and alters brain de-
velopment. We previously reported that 80 mg/kg/day of DEA
during pregnancy in mice reduced neurogenesis and increased
apoptosis in the fetal hippocampus. This study was designed to
establish the dose-response relationships for this effect of DEA.
Timed-pregnant C57BL/6 mouse dams were dosed dermally from
gestation day 7–17 with DEA at 0 (controls), 5, 40, 60, and 80 mg/kg
body/day. Fetuses (embryonic day 17 [E17]) from dams treated
dermally with 80 mg/kg body/day DEA had decreased neural
progenitor cell mitosis at the ventricular surface of the ventricular
zone (hippocampus, 54.1 ± 5.5%; cortex, 58.9 ± 6.8%; compared
to controls; p < 0.01). Also, this dose of DEA to dams increased
rates of apoptosis in E17 fetal hippocampus (to 177.2 ± 21.5%
of control; measured using activated caspase-3; p < 0.01). This
dose of DEA resulted in accumulation of DEA and its
metabolites in liver and in plasma. At doses of DEA less than
80 mg/kg body/day to dams, there were no differences between
treated and control groups. In a small group of human subjects,
dermal treatment for 1 month with a commercially available
skin lotion containing 1.8 mg DEA per gram resulted in
detectable plasma concentrations of DEA and dimethyldietha-
nolamine, but these were far below those concentrations
associated with perturbed brain development in the mouse.
Key Words: diethanolamine; choline; pregnancy; brain
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Diethanolamine (DEA) (Chemical Abstracts Registration
Number 111-42-2) is widely used as a chemical intermediate,
as an anticorrosion agent in metalworking fluids and as
a surfactant component in cosmetic formulations, pharmaceut-
icals, and agricultural products (CIR, 1983, 1986). The most
probable route of environmental exposure to DEA in humans is
via dermal exposure to personal care products (i.e., skin
lotions, soaps, shampoos, and cosmetics), detergents, and other
surfactants that contain DEA; cosmetic formulations may have
concentrations of DEA ranging from 0.1 to 5% (CIR, 1983).
DEA is structurally similar to the essential nutrient choline,
and DEA treatment in rodents perturbed choline metabolite
concentrations in liver (Lehman-McKeeman et al., 2002; Stott
et al., 2000). DEA is metabolized by routes common to
endogenous alkanolamines (ethanolamine and choline) and is
incorporated into phospholipids in liver, kidney, spleen, and
brain of mice and rats (Mathews et al., 1995), probably by the
enzyme-catalyzed transphosphatidylation of phosphatidylcho-
line (PtdCho) by phospholipase D (Dippe et al., 2008).
Furthermore, DEA inhibits PtdCho synthesis in rat liver tissue
in vitro (Barbee and Hartung, 1979) and in vivo (Browning and
Snyder, 1987). Also, DEA is an inhibitor of choline transport
into neural progenitor cells (Niculescu et al., 2007).
Maternal choline deficiency during pregnancy in the rodent
results in diminished proliferation and increased apoptosis of
neural progenitor cells in the fetal hippocampus (Albright
et al., 1999; Craciunescu et al., 2003), and these result in
lifelong changes in memory performance (Meck and Williams,
2003; Meck et al., 1988). Similarly, DEA administration
(80 mg/kg/day) during pregnancy caused diminished pro-
liferation and increased apoptosis of neural progenitor cells in
the fetal hippocampus (Craciunescu et al., 2006), probably by
perturbing choline metabolism. The present study reports that
the effects of DEA during pregnancy were only observed at the
highest dose that was tested (80 mg/kg body weight/day to the
dams from days 11 to 17 or pregnancy) and were not detected
at lower doses. These exposure data should be useful in the
evaluation of the safety of cosmetic and other personal care
products and ingredients containing DEA.
MATERIALS AND METHODS
Animals
Timed-pregnant C57BL/6 mice (the morning when the vaginal plug was
observed after mating was considered embryonic day 0 of gestation) were used
1 To whom correspondence should be addressed at CB#7461, 2115A Michael
Hooker Research Center, University of North Carolina at Chapel Hill, Chapel
Hill, NC 27599-7461. Fax: (919)-843-8555; E-mail: steven_zeisel@unc.edu.
 The Author 2008. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved.
For permissions, please email: journals.permissions@oxfordjournals.org
in all experiments and were obtained from The Jackson Laboratories (Bar
Harbor, ME) on day 7 of gestation, maintained in a climate-controlled
environment and exposed to a 12-h light/dark cycle daily. All animal protocols
were approved by the UNC Institutional Animal Use Committee. Mice were
fed purified AIN-76A diet containing 1.1 g/kg (7.8 mmol/kg) choline chloride
(Dyets, Bethlehem, PA) and water ad libitum unless otherwise noted.
A total of 59 female mice were used; three groups of seven mice were treated
with vehicle (control) from gestation day embryonic day 7 (E7) through E17,
one group of seven mice for each DEA dose (5, 40, 60, and 80 mg/kg body
weight) was treated for the same period, one group of five nonpregnant female
mice was treated with vehicle for 11 days, and one group of five nonpregnant
female mice was treated with 80 mg/kg body weight/day DEA for 11 days. The
animals were dosed dermally with DEA (BioUltra > 99.5% purity; Sigma-
Aldrich, St Louis, MO) dissolved in acetone at 0, 5, 40, 60, and 80 mg/kg body
weight/day from gestation day E7 through E17. The dose formulations were
prepared so as to deliver the desired dose in the same volume of acetone (1.78 ll/g
mouse weight) over the prepared target site using a micropipetter equipped with
a blunted tip. The dose formulations were stored at 4C, protected from light,
in polyethylene vials. All dose formulation samples were within 5% of the
target concentrations (we analyzed the composition of the last vial used in each
treatment using the liquid chromatography-electrospray ionization-mass
spectrometry [LC-ESI-MS] method described later). Dermal application of
DEA to pregnant dams and tissue collection on gestational day 17 were
conducted as described previously (Craciunescu et al., 2006).
Two male fetal brains from each dam were embedded in paraffin, and 5-lm
coronal serial sections containing the brain regions of interest such as the
hippocampus and cortex were cut and applied on glass slides for histological
and immunohistochemical assays. Since there is a posterior to anterior gradient
of neurogenesis in fetal mouse brain, the sections were reviewed at the time of
immunostaining to ensure that they included anatomically reproducible areas of
the hippocampus as defined by a standard atlas of the developing brain
(Jacobowitz and Abbott, 1998). In prenatal and early postnatal stages,
neurogenesis occurs mostly within two relatively thin layers of tissue lining
the primitive ventricular cavities, referred to as the ventricular zone (VZ) and
the subventricular zone (SVZ) (The Boulder Committee 1970)
Each immunohistochemical assay was replicated on subsequent serial
sections and on littermate male fetus brains.
Human Subjects
Healthy premenopausal female subjects (aged 20–45 years) of any race or
ethnicity were recruited from the local area for a 1-month study approved by
the Public Health Institutional Review Board at the University of North
Carolina at Chapel Hill. The study was advertised using IRB-approved flyers
placed on bulletin boards in target locations. Prospective subjects who con-
tacted us with an interest in the study were prescreened by telephone. Inclusion
was contingent on a good state of health (no acute or chronic disease) and
willingness to participate in an outpatient setting. Women who were pregnant
or planning to get pregnant in the next 6 months were excluded. Three
prospective subjects indicated that they had an interest in the study; all three
met eligibility criteria and were enrolled. The three subjects were 30, 30, and
29 years of age, two were Caucasian, and one was Asian. Informed consent,
approved by the UNC Public Health IRB, was obtained from all subjects prior
to initiating any study-related procedure.
Subjects were asked to come in for three study visits—day 0 (baseline),
1 week, and 1 month (end of treatment). At the baseline visit, subjects were
given a supply of 929 g of a commercially available body lotion (containing
1.8 mg DEA/g lotion measured using the LC-ESI-MS method described later)
placed in an unmarked bottle. Subjects were blinded against the product’s
brand identification. Subjects were asked to begin using the lotion the following
day (day 1) and to continue applying the lotion for the duration of the study
(1 month). The subjects were instructed to apply the lotion to their whole body
(per the manufacturer’s instructions) twice per day—in the morning after
showering and again before bedtime. Compliance with the body lotion regimen
was monitored by having the participants keep a log of daily application and by
visually inspecting and weighing the bottle of lotion at the 1-week and 1-month
follow-up visits. At each visit, subjects were monitored for pregnancy using
a commercially available urine pregnancy test. Whole blood (7 ml) was
collected in EDTA BD Vacutainer tubes by venipuncture at the baseline (1 day
before treatment), 1-week, and 1-month (end of treatment) study visits, between
8:00 and 10:00 A.M. DEA and metabolites were assayed in plasma. Two
subjects completed the study per protocol and used the body lotion for the full
1-month period. One subject voluntarily dropped out of the study after 3 weeks
of participation. For this subject, a 3-week whole-blood sample was collected in
place of the 1-month measurement.
Assessment of Mitosis
The mitotic and synthetic zone of the VZ adjacent to the lateral ventricle is
the region of fetal hippocampus from which neuronal and glial type cells
originate (Altman and Bayer, 1990). The cells at the ventricular surface of the
VZ of the developing hippocampus include progenitor cells that have exited the
S phase and entered the mitotic phase of the cell cycle. To determine whether
mitosis in fetal hippocampus was altered by maternal dermally administered
DEA during pregnancy, coronal sections were probed with a rabbit polyclonal
antibody that recognizes phosphorylated histone H3 (phospho-H3; Upstate,
Lake Placid, NY) as previously described (Craciunescu et al., 2006). Histone
H3 is the core protein of the nucleosome that becomes Ser-10 phosphorylated
in the G2/M phase (Hendzel et al., 1997). This phosphorylation is essential for
the maintenance of mitosis-associated chromosome condensation (Hans and
Dimitrov, 2001).
The incidence of phospho-histone H3-labeled cells was measured at the
ventricular surface of the VZ beginning at the junction of the hippocampus and
choroid plexus (hippocampal wedge [Altman and Bayer, 1990]) and extending
toward and over the cortical VZ. Cells were counted at a final magnification of
3200 in 6–12 hippocampal hemispheres from three to six consecutive serial
sections, and the values were averaged to obtain a single value/hippocampus
(cortex)/animal. Calibrated 340 magnification images of the same regions were
used to measure the length of the hippocampal SVZ with an internal macro of
NIH Image J program version 1.61. Analyses were replicated on subsequent
serial sections, with similar results.
Assessment of Apoptosis
Activated caspase-3 immunoreactivity was used to detect apoptotic cells in
fetal hippocampus. The pretreatment of slides for deparaffinization, antigen
retrieval, and blocking was identical to the one for mitosis assessment and was
followed by overnight incubation with a primary antibody to cleaved
(activated) caspase-3 (Asp175) (Cell Signaling Technology, Beverly, MA).
Then, goat Cy3-anti-rabbit IgG (Chemicon, Temecula, CA) was applied for 2 h
at room temperature to display the activated caspase-3. 4’,6-Diamidino-2-
phenylindole (DAPI; Sigma-Aldrich, St Louis, MO), 0.1 lg/ml, for 20 min was
used to counterstain nuclear DNA. The activated caspase-3-positive cells were
identified and scored by a trained observer, blinded to the animal’s grouping,
based upon the presence of yellow fluorescent staining for activated caspase-3.
Stained nuclei were usually, but not always, condensed, and intense blue
fluorescent chromatin was often visible inside, consistent with fragmented
DNA. Apoptotic indices for the fetal mouse brain hippocampus of the different
animal groupings are presented as the number of apoptotic cells/hippocampal
section. In all, 6–12 hippocampal hemispheres from three to six consecutive
serial sections were averaged to obtain single value/hippocampal section/animal.
Image Analysis
For mitosis assessment and activated caspase-3 evaluation, the image
analysis of fetal brain slices was performed using a Zeiss Confocal Laser
Scanning Microscope LSM 210 (Carl Zeiss, Thornwood, NY) equipped with
an Optronics DEI 750 low light level–integrating CCD camera (Optronics
Engineering, Goleta, CA) connected to an Apple Macintosh G3 computer
utilizing a Scion CG7 image capture card for digital image capture of standard
and epifluorescence images and the public domain NIH Image J program
version 1.61. For the replicated experiments, the apoptotic cells were detected
DOSE RESPONSE TO DEA 221
hemilaterally in each of the selected sections after labeling for activated
caspase-3 using a Nikon FXA microscope (Nikon, Garden City, NY)
equipped with an Optronics TEC-470 CCD Video Camera System (Optronics
Engineering) and the public domain NIH Image J program version 1.61. All
images were captured by using 35, 320, or 340 objectives and fluorescent
filters optimized for observing DAPI (blue), erythrocyte autofluorescence
(green, using filter XF 100-2; Omega Opticals, Brattleboro, VT), and Cy3
conjugates (yellow, XF 108-2; Omega Opticals) signals, respectively. Images
obtained from the same field with different fluorescent probes were
subsequently overlapped or merged.
Analysis of Choline and Diethanolamine Compounds
Reagents. Betaine, choline chloride, glycerophosphocholine (GPCho),
phosphocholine (PCho), DEA, and N-methyldiethanolamine were ordered from
Sigma Chemicals (St Louis, MO). Bis(2-hydroxyethyl)dimethylammonium
chloride was obtained from Acros Organic (Fair Lawn, NJ). Choline-[N,N,N-
trimethyl-d9] bromide, betaine-[N,N,N-trimethyl-d9] hydrochloride, and phos-
phocholine-[N,N,N-trimethyl-d9] chloride were purchased from CNS isotopes
(Quebec, Canada). Glycerophosphocholine-[N,N,N-trimethyl-d9] was synthe-
sized as described elsewhere (Koc et al., 2002). 1,2-Dipalmitoyl-sn-3-
glycerophosphocholine-[N,N,N-trimethyl-d9] was purchased from Avanti Polar
Lipids (Alabaster, AL). Bis(2-hydroxyethyl)-d8-amine was obtained from
Cambridge Isotope Laboratories, Inc. (Andover, MA). All solvents used were
of high-performance liquid chromatography grade.
LC-ESI-MS analysis. Choline, betaine, PCho, GPCho, PtdCho, and
sphingomyelin (SM) were determined in maternal liver using liquid chromatog-
raphy-electrospray ionization-isotope dilution mass spectrometry (LC-ESI-
IDMS; LCQ quadrupole ion trap mass spectrometer equipped with an API2
electrospray ionization source; ThermoQuest, San Jose, CA) as previously
described (Koc et al., 2002). The same method, using selected reaction
monitoring mode, was used for analysis of DEA and its metabolites in tissues,
dose formulations, and body lotion. For DEA (m/z 106), monomethyldiethanol-
amine (MDEA) (m/z 120) and dimethyldiethanolamine (DMDEA) (m/z 134) in
aqueous phase, m/z value of 88, 102, and 90, respectively, were monitored with
DEA-d8 (m/z 96) as an internal standard. For phosphatidyldiethanolamine
(PtdDEA), phosphatidylmonomethyldiethanolamine (PtdMDEA), and phospha-
tidyldimethyldiethanolamine (PtdDMDEA), a source collision energy of 35 eV,
followed by and a further collision energy of 25 eV was used to achieve the
characterization fragment (m/z 88, 102, 116, and 104) since no commercial
standards were available (PtdCho-d9 was used as an internal standard).
Briefly, deuterium-labeled internal standards of choline, betaine, DEA,
GPCho, PCho, SM, and PtdCho and 400 ll of methanol/chloroform (2:1, vol/
vol) were added to 100-mg aliquots of tissue. Samples were vortexed
vigorously and left at – 20C overnight. At the end of the extraction, samples
were subjected to centrifugation at 1500 3 g for 5 min at room temperature.
The supernatant was transferred to a new tube, and the residue was reextracted
with 250 ll of methanol/chloroform/water (2:1:0.8, by volume). The super-
natants from both extractions were combined. To the combined solution, 100 ll
of chloroform and then 100 ll of water were added to form two phases. After
centrifugation at 1500 3 g for 5 min, the aqueous phase (which contained
choline) was separated from the chloroform phase (which contained PtdCho
and SM). A 10-ll aliquot of the lower organic phase was analyzed by LC-ESI-
IDMS directly. The aqueous phase was dried by vacuum centrifugation (Speed-
Vac; Savant Instruments, Farmingdale, NY) and redissolved in 20 ll of water.
Following addition of 200 ll of methanol, the aqueous phase was subjected to
centrifugation at 1500 3 g for 5 min to remove the precipitated unknown
compounds from the solution. A 10-ll aliquot of this solution was then
analyzed by LC-ESI-IDMS.
Data collection and analysis were performed by Xcalibur software
(ThermoQuest, San Jose, CA) running on Windows NT4.0.
Statistical Analysis
All statistical analyses were performed with JMP software (V 2; SAS Institute,
Cary, NC). Data are presented as mean ± SE.
RESULTS
DEA and Choline Metabolites after Treatment
Treatment of adult female mice with 80 mg/kg body/day
DEA for 11 days increased concentrations of DEA, MDEA,
DMDEA, PtdDEA, PtdMDEA, and PtdDMDEA in liver and
plasma (Table 1). Many of the DEA metabolites achieved
higher concentrations in liver than in plasma (Table 1).
Application of commercial body lotion containing DEA to the
skin of humans for 1 month also resulted in increased con-
centrations of DEA and DMDEA in plasma (Fig. 1), though the
concentrations achieved were approximately 100- to 200-fold
lower than those observed in mice after the 80 mg/kg body/day
DEA dose for 11 days. Blanks, run simultaneously, were at
least twofold lower than the values measured in plasma or liver
from untreated control mice or humans.
Treatment of adult female mice with 80 mg/kg body/day
DEA for 11 days decreased hepatic concentrations of choline
and all its metabolites (Table 2). PCho, a major storage pool of
choline in liver, was decreased to 38% of control (p < 0.01);
PtdCho, another major storage pool, was decreased to 53% of
control (p < 0.01); and betaine, a metabolite of choline used as
a methyl donor, was decreased to 41% of control (p < 0.01).
Mitosis in Fetal Brain
Proliferation of neural progenitor cells in E17 brain VZs of
hippocampus and cortex was assessed using immunohisto-
chemistry for phospho-histone H3. Typical distribution of
mitotic cells in periventricular zones is presented in Figure 2,
upper panels. In both regions studied, only the treatment with
80 mg/kg/day DEA diminished the proportion of cells that
were in the mitotic phase to approximately 50% of control (p <
0.01 different from control; Fig. 3; for cortical VZ, the data are
TABLE 1
DEA and Its Methylated Metabolites Accumulated in Liver and
Plasma of Female Mice Dermally Treated with 80 mg DEA/kg
body/day
Liver (nmol/g) Plasma (nmol/ml)
Control DEA Control DEA
DEA 0 8958 ± 965** 58 ± 27 1253 ± 127**
MDEA 100 ± 13 1549 ± 219** 0 405 ± 76**
DMDEA 3.2 ± 0.6 1216 ± 101** 14 ± 6 106 ± 16**
PtdDEA 0 2.4 ± 0.3** 0 4.3 ± 1.1**
PtdMDEA 0 24 ± 2** 0 11 ± 2**
PtdDMDEA 0 137 ± 8** 0 243 ± 17**
Note. Female mice were dermally treated with 80 mg/kg body/day DEA or
vehicle control for 11 days as described in the text. DEA and its metabolites
were assayed in plasma and liver using LC-ESI-IDMS. Results are presented as
mean ± SE; n ¼ 5 animals/group. **p < 0.01 DEA-treated group differs from
the control group by ANOVA and Tukey-Kramer test.
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similar to that from hippocampus and are not shown). DEA
treatment did not alter the length of the VZs.
Apoptosis in Fetal Brain
Apoptosis was assessed in E17 brain hippocampus using
immunohistochemistry for activated caspase-3. Typical apo-
ptotic cells expressing activated caspase-3 in hippocampus are
shown in Figure 2, lower panels. The number of apoptotic cells
was increased 1.75-fold in fetuses from 80 mg/kg body/day
DEA-treated dams compared to the controls (p < 0.01, Fig. 4).
Apoptosis was not increased at any of the lower doses of DEA.
DISCUSSION
The present study confirmed earlier results that showed that
80 mg/kg/day DEA administered to pregnant mouse dams
resulted in depletion of choline metabolites in maternal liver as
well as in diminished neural progenitor cell proliferation and
increased apoptosis in fetal brain (Craciunescu et al., 2006).
Also confirmed was the observation that hepatic stores of
choline were depleted in nonpregnant rats treated with DEA
(Lehman-McKeeman et al., 2002). The present study now adds
the observations that DEA treatment resulted in accumulation
of DEA and its metabolites in maternal liver and plasma, that
humans applying commercial skin lotion also absorb small
amounts of DEA, and that the lowest effect (altered fetal brain
progenitor cell proliferation or apoptosis) level of DEA in mice
is at or near to 80 mg/kg/day applied dermally.
DEA and its N-methylated metabolites accumulated in both
liver and plasma of treated mice (Table 1) achieving 10-fold
higher concentrations in tissues than in blood. We confirmed
earlier observations (Mathews et al., 1995) that DEA can
substitute for the choline head group in membrane phospho-
lipids, forming PtdDEA, PtdMDEA, and PtdDMDEA. This
could alter membrane function. Untreated mice had detectable
(well above blank), though low, concentrations of DEA
metabolites in liver and plasma. This suggests that there is an
environmental source of exposure in laboratory mice, perhaps,
from solutions used to wash cages or bottles.
Human exposure to alkanolamines such as DEA occurs
mainly through the skin (Henriks-Eckerman et al., 2007). Four
weeks of application of a commercially available DEA-
containing body lotion to a small group of humans resulted
in plasma concentrations of DEA and metabolites that were
significantly increased above blank values but that were
approximately 100- to 200-fold lower than those achieved in
mice treated with the 80 mg/kg/day dose. The subjects applied
between 14.5 and 22.9 ml/day (based on returned bottle content
of lotion). A 60-kg person applying 20 ml/day of this strength
lotion was exposed to a DEA dose of 0.6 mg/kg/day. In a few
weeks of application, the three subjects achieved concen-
trations of DEA and metabolites in plasma that were
approximately 0.5–1% of the concentrations achieved after
the mice were treated with 80 mg/kg/day for 11 days. Since the
TABLE 2
Concentrations of Choline and Its Metabolites Decreased in




Choline 777 ± 71 232 ± 14**
PtdCho 15,407 ± 1464 8192 ± 527**
SM 1351 ± 52 906 ± 35*
Betaine 543 ± 73 223 ± 68**
GPCho 157 ± 55 9.5 ± 3.6**
PCho 300 ± 24 113 ± 8**
Note. Female mice were dermally treated with 80 mg/kg body/day DEA or
vehicle control for 11 days as described in text. Choline and its metabolites
were assayed using LC-ESI-IDMS. Results are presented as the mean ± SE;
n¼5 animals/group. *p< 0.05; **p< 0.01 DEA-treated group differs from the
control group by ANOVA and Tukey-Kramer test.
FIG. 1. DEA and its metabolite DMDEA accumulated in humans who applied DEA-containing lotion to their skin. Three healthy women applied
a commercially available skin lotion that contained DEA (0.18% wt/vol) each day for the time indicated as described in the text. DEA and its metabolites were
assayed in plasma using LC-ESI-IDMS. Data from each subject are separately presented.
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dose administered was 133-fold lower, it is not surprising that
the concentrations achieved were proportionately lower. It is
noticeable that all three subjects had low, but detectable,
concentrations of DEA in plasma at baseline (Fig. 1),
suggesting that humans are exposed to DEA in the environ-
ment. The human data from the present study should be
considered as pilot data; only three subjects were studied (one
for 3 weeks rather than a month), and there was significant
variability among subjects. A larger group should be studied
prior to making definitive conclusions and quantitative risk
estimates using this data. The human data are presented to
provide an estimate of the order or magnitude of response to
exposure in humans relative to the mouse.
Because personal care products and cosmetics (CIR, 1983)
contain no more than 5% DEA and human skin is not very
permeable to DEA (Brain et al., 2005; Kraeling et al., 2004), it
is unlikely that humans using these products will be exposed to
the amounts of DEA that we report to have effects on mouse
brain development (based on the current study, if a 60-kg body
weight human used 20 ml of a product containing 5% DEA
daily, estimated exposure would be 16.6 mg/kg/day.) Occupa-
tional exposure to DEA is most likely through the use of
lubricating liquids in machining operations; DEA is a compo-
nent of bulk cutting fluids, which contain 4–5% DEA by
weight but are normally diluted 20-fold before use (Technol-
ogy Planning and Management Corporation, 2002). The
National Institute for Occupational Safety and Health estimates
that the number of workers potentially exposed to DEA is
approximately 800,000/year (Technology Planning and Man-
agement Corporation, 2002). Annual production of DEA in the
United States was estimated at 106,000 tons in 1995
FIG. 2. Immunohistochemical analysis of cell proliferation and caspase-3 activation in fetal E17 mouse hippocampus. Pregnant mice were treated dermally
with 80 mg/kg/day DEA (or vehicle control) from E7 until they were killed on E17. Coronal sections were prepared from the brains of fetuses from each group for
the analysis of mitosis using the mitosis-specific marker phosphorylated histone H3 and apoptosis as described in text. Representative images for mitosis in fetal
brain hippocampus at 340 magnification are shown in the upper panels; CT for controls (results were similar for all the no-effect doses; 5, 40, and 60 mg/kg/day
DEA). The boxed area in the lower left panel is shown at 3400 magnification in the lower right panel and presents active caspase-3-positive cells. The DAPI
nuclear DNA counterstaining is blue, while the Cy3 conjugated secondary antibody bound to the anti-phospho-histone H3 (ser10) or anti-active caspase-3 primary
antibody stains bright yellow.
FIG. 3. Quantitative analysis of mitosis in hippocampal sections from fetal
mice at E17. Pregnant mice were treated with DEA and fetal hippocampal
sections and prepared as presented in Figure 2. Images were analyzed in an
unbiased blinded manner as described in text. Pooled data from the dose
treatment experiments are presented as mean number of mitotic cells (±SE) at
the ventricular surface of the hippocampal VZ. Open bars ¼ vehicle control;
shaded bars ¼ DEA dose treated. Similar results (data not shown) were
obtained for the ventricular surface of cortical VZ. Results are presented as the
mean ± SE. n ¼ 7 animals per group; **p < 0.01 different from control in same
brain region by ANOVA and Tukey-Kramer test.
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(Technology Planning and Management Corporation, 2002).
Again, rough calculations suggest that occupational exposure
to DEA will not approach the 80 mg/kg/day dose needed to
alter neurogenesis in mice. These conclusions should be used
cautiously as it is possible that human embryonic hippocampus
is more sensitive to DEA than is mouse hippocampus. Also, the
present study only administered DEA lotion to subjects for 1
month; humans could use such products daily for a lifetime.
Excellent reviews exist that summarize the toxicology of DEA
(IARC, 2000; Leung et al., 2005).
This study identifies the dose-response relationship for mouse
embryotoxicity of DEA, a common commercial ingredient in
personal care goods, and we present pilot data that suggest that
human exposure is likely to be on the order of 100- to 200-fold
lower than that needed to perturb brain development in the
mouse.
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